Literature DB >> 21644014

Molecular modeling studies on phosphonic acid-containing thiazole derivatives: design for fructose-1,6-bisphosphatase inhibitors.

Ping Lan1, Zhi-Wei Wu, Wan-Na Chen, Ping-Hua Sun, Wei-Min Chen.   

Abstract

Presently, an in silico modeling was carried out on a series of 63 phosphonic acid-containing thiazole derivatives as fructose-1,6-bisphosphatase (FBPase) inhibitors using CoMFA/CoMSIA and molecular docking methods. The CoMFA and CoMSIA models using 51 molecules in the training set gave r (cv) (2) values of 0.675 and 0.619, r ( 2 ) values of 0.985 and 0.979, respectively. The systemic external validation indicated that our CoMFA and CoMSIA models possessed high predictive powers with r (0) (2) values of 0.995 and 0.994, r (m(test)) (2) values of 0.887 and 0.860, respectively. The 3D contour maps of the CoMFA and CoMSIA provided smooth and interpretable explanation of the structure-activity relationship for the inhibitors. Molecular docking studies revealed that a phosphonic group was essential for binding to the AMP binding site, and some key features were also identified. The analyses of the 3D contour plots and molecular docking results permitted interesting conclusions about the effects of different substituent groups at different positions of the common scaffold, which might guide the design of novel FBPase inhibitors with higher activity and bioavailability. A set of 60 new analogues were designed by utilizing the results revealed in the present study, and were predicted with significantly improved potencies in the developed models. The findings can be quite useful to aid the designing of new fructose-1,6-biphophatase inhibitors with improved biological response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21644014     DOI: 10.1007/s00894-011-1134-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  28 in total

1.  3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA.

Authors:  Somayeh Pirhadi; Jahan B Ghasemi
Journal:  Eur J Med Chem       Date:  2010-08-10       Impact factor: 6.514

2.  A prodrug approach towards the development of tricyclic-based FBPase inhibitors.

Authors:  Tomoharu Tsukada; Kazuhiko Tamaki; Jun Tanaka; Toshiyuki Takagi; Taishi Yoshida; Akira Okuno; Takeshi Shiiki; Mizuki Takahashi; Takahide Nishi
Journal:  Bioorg Med Chem Lett       Date:  2010-03-07       Impact factor: 2.823

3.  Role of enzyme-enzyme interactions in the regulation of gluconeogenesis. Properties and subunit structure of fructose 1,6-diphosphatase from swine kidney.

Authors:  J Mendicino; N Kratowich; R M Oliver
Journal:  J Biol Chem       Date:  1972-10-25       Impact factor: 5.157

4.  Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.

Authors:  Qun Dang; Yan Liu; Daniel K Cashion; Srinivas Rao Kasibhatla; Tao Jiang; Frank Taplin; Jason D Jacintho; Haiqing Li; Zhili Sun; Yi Fan; Jay DaRe; Feng Tian; Wenyu Li; Tony Gibson; Robert Lemus; Paul D van Poelje; Scott C Potter; Mark D Erion
Journal:  J Med Chem       Date:  2010-12-02       Impact factor: 7.446

5.  3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.

Authors:  Ping Lan; Zhi-Jian Huang; Jun-Rong Sun; Wei-Min Chen
Journal:  Int J Mol Sci       Date:  2010-09-17       Impact factor: 5.923

6.  Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.

Authors:  Qun Dang; Srinivas Rao Kasibhatla; Tao Jiang; Kevin Fan; Yan Liu; Frank Taplin; William Schulz; Daniel K Cashion; K Raja Reddy; Paul D van Poelje; James M Fujitaki; Scott C Potter; Mark D Erion
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

7.  Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.

Authors:  Gustavo H G Trossini; Rafael V C Guido; Glaucius Oliva; Elizabeth I Ferreira; Adriano D Andricopulo
Journal:  J Mol Graph Model       Date:  2009-03-14       Impact factor: 2.518

8.  Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.

Authors:  Qun Dang; Srinivas Rao Kasibhatla; K Raja Reddy; Tao Jiang; M Rami Reddy; Scott C Potter; James M Fujitaki; Paul D van Poelje; Jingwei Huang; William N Lipscomb; Mark D Erion
Journal:  J Am Chem Soc       Date:  2007-11-28       Impact factor: 15.419

9.  CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-10-01       Impact factor: 1.810

10.  Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus.

Authors:  G Yamanaka; T Wilson; S Innaimo; G S Bisacchi; P Egli; J K Rinehart; R Zahler; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.938

View more
  2 in total

1.  In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.

Authors:  Ming Hao; Xiaole Zhang; Hong Ren; Yan Li; Shuwei Zhang; Fang Luo; Mingjuan Ji; Guohui Li; Ling Yang
Journal:  Int J Mol Sci       Date:  2011-11-18       Impact factor: 5.923

2.  Toward the prediction of FBPase inhibitory activity using chemoinformatic methods.

Authors:  Ming Hao; Shuwei Zhang; Jieshan Qiu
Journal:  Int J Mol Sci       Date:  2012-06-07       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.